{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:51:17Z","timestamp":1785336677451,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100011447","name":"Science and Technology Department of Henan Province","doi-asserted-by":"publisher","award":["242102311123"],"award-info":[{"award-number":["242102311123"]}],"id":[{"id":"10.13039\/501100011447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011447","name":"Science and Technology Department of Henan Province","doi-asserted-by":"publisher","award":["53"],"award-info":[{"award-number":["53"]}],"id":[{"id":"10.13039\/501100011447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011447","name":"Science and Technology Department of Henan Province","doi-asserted-by":"publisher","award":["235200810034"],"award-info":[{"award-number":["235200810034"]}],"id":[{"id":"10.13039\/501100011447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018925","name":"Health Commission of Henan Province","doi-asserted-by":"publisher","award":["HNMOT2024015"],"award-info":[{"award-number":["HNMOT2024015"]}],"id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018925","name":"Health Commission of Henan Province","doi-asserted-by":"publisher","award":["SBGJ202301004"],"award-info":[{"award-number":["SBGJ202301004"]}],"id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573686"],"award-info":[{"award-number":["82573686"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-26828-x","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:23:48Z","timestamp":1764325428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ifebemtinib and paclitaxel synergistically inhibit the proliferation and metastasis of TNBC by blocking PI3K\/Akt pathway through LSD1\/PIK3IP1 axis"],"prefix":"10.1038","volume":"15","author":[{"given":"Yong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"26828_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"26828_CR2","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N Engl. J. Med. 363, 1938\u20131948 (2010).","journal-title":"N Engl. J. Med."},{"key":"26828_CR3","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1002\/cncr.27581","volume":"118","author":"NU Lin","year":"2012","unstructured":"Lin, N. U. et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National comprehensive cancer network. Cancer 118, 5463\u20135472 (2012).","journal-title":"Cancer"},{"key":"26828_CR4","doi-asserted-by":"publisher","first-page":"1274209","DOI":"10.3389\/fphar.2024.1274209","volume":"15","author":"HH Hu","year":"2024","unstructured":"Hu, H. H. et al. Roles and inhibitors of FAK in cancer: current advances and future directions. Front. Pharmacol. 15, 1274209 (2024).","journal-title":"Front. Pharmacol."},{"key":"26828_CR5","doi-asserted-by":"publisher","first-page":"14535","DOI":"10.1038\/s41598-025-98661-1","volume":"15","author":"X Wu","year":"2025","unstructured":"Wu, X. et al. Leucine rich repeat containing 15 promotes triple-negative breast cancer proliferation and invasion via the ITGB1\/FAK\/PI3K signalling pathway. Sci. Rep. 15, 14535 (2025).","journal-title":"Sci. Rep."},{"key":"26828_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","volume":"21","author":"JC Dawson","year":"2021","unstructured":"Dawson, J. C., Serrels, A., Stupack, D. G., Schlaepfer, D. D. & Frame, M. C. Targeting FAK in anticancer combination therapies. Nat. Rev. Cancer. 21, 313\u2013324 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"26828_CR7","doi-asserted-by":"publisher","first-page":"eaax8933","DOI":"10.1126\/scitranslmed.aax8933","volume":"14","author":"G Lorusso","year":"2022","unstructured":"Lorusso, G. et al. Connexins orchestrate progression of breast cancer metastasis to the brain by promoting FAK activation. Sci. Transl Med. 14, eaax8933 (2022).","journal-title":"Sci. Transl Med."},{"key":"26828_CR8","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1038\/s41467-022-30105-0","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. EZH2 engages TGFbeta signaling to promote breast cancer bone metastasis via integrin beta1-FAK activation. Nat. Commun. 13, 2543 (2022).","journal-title":"Nat. Commun."},{"key":"26828_CR9","doi-asserted-by":"crossref","unstructured":"Pang, X. J. et al. Drug discovery targeting focal adhesion kinase (FAK) as a promising cancer therapy. Molecules 26, 4250 (2021).","DOI":"10.3390\/molecules26144250"},{"key":"26828_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41389-018-0032-z","volume":"7","author":"UA Hirt","year":"2018","unstructured":"Hirt, U. A. et al. Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype. Oncogenesis 7, 21 (2018).","journal-title":"Oncogenesis"},{"key":"26828_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12672-021-00425-6","volume":"12","author":"H Li","year":"2021","unstructured":"Li, H., Gao, Y. & Ren, C. Focal adhesion kinase inhibitor BI 853520 inhibits cell proliferation, migration and EMT process through PI3K\/AKT\/mTOR signaling pathway in ovarian cancer. Discov Oncol. 12, 29 (2021).","journal-title":"Discov Oncol."},{"key":"26828_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13046-024-02974-4","volume":"43","author":"B Zhang","year":"2024","unstructured":"Zhang, B. et al. Targeting of focal adhesion kinase enhances the Immunogenic cell death of pegylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint Blockade. J. Exp. Clin. Cancer Res. 43, 51 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"26828_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.20892\/j.issn.2095-3941.2020.0273","volume":"18","author":"A Osipov","year":"2021","unstructured":"Osipov, A. et al. Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8\u2009+\u2009T cells. Cancer Biol. Med. 18, 206\u2013214 (2021).","journal-title":"Cancer Biol. Med."},{"key":"26828_CR14","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1038\/s41401-024-01312-w","volume":"45","author":"MS Xu","year":"2024","unstructured":"Xu, M. S. et al. A novel FAK-degrading PROTAC molecule exhibited both anti-tumor activities and efficient MDR reversal effects. Acta Pharmacol. Sin. 45, 2174\u20132185 (2024).","journal-title":"Acta Pharmacol. Sin"},{"key":"26828_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40364-024-00558-0","volume":"12","author":"X Tan","year":"2024","unstructured":"Tan, X. et al. Simultaneous Inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling. Biomark. Res. 12, 13 (2024).","journal-title":"Biomark. Res."},{"key":"26828_CR16","doi-asserted-by":"publisher","first-page":"111536","DOI":"10.1016\/j.isci.2024.111536","volume":"28","author":"B Zhang","year":"2025","unstructured":"Zhang, B. et al. Targeting FAK improves the tumor uptake of antibody-drug conjugates to strengthen the anti-cancer responses. iScience 28, 111536 (2025).","journal-title":"iScience"},{"key":"26828_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11523-018-00617-1","volume":"14","author":"MJA de Jonge","year":"2019","unstructured":"de Jonge, M. J. A. et al. Phase I study of BI 853520, an inhibitor of focal adhesion Kinase, in patients with advanced or metastatic nonhematologic malignancies. Target. Oncol. 14, 43\u201355 (2019).","journal-title":"Target. Oncol."},{"key":"26828_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11523-019-00620-0","volume":"14","author":"T Doi","year":"2019","unstructured":"Doi, T. et al. Phase I study of the focal adhesion kinase inhibitor BI 853520 in Japanese and Taiwanese patients with advanced or metastatic solid tumors. Target. Oncol. 14, 57\u201365 (2019).","journal-title":"Target. Oncol."},{"key":"26828_CR19","doi-asserted-by":"publisher","first-page":"e2100250","DOI":"10.1002\/advs.202100250","volume":"8","author":"B Zhang","year":"2021","unstructured":"Zhang, B. et al. Focal adhesion kinase (FAK) Inhibition synergizes with KRAS G12C inhibitors in treating cancer through the regulation of the FAK-YAP signaling. Adv. Sci. (Weinh). 8, e2100250 (2021).","journal-title":"Adv. Sci. (Weinh)"},{"key":"26828_CR20","doi-asserted-by":"crossref","unstructured":"Peyvandi, S. et al. Tumor-educated Gr1\u2009+\u2009CD11b\u2009+\u2009cells drive breast cancer metastasis via OSM\/IL-6\/JAK-induced cancer cell plasticity. J Clin. Invest 134, e166847 (2024).","DOI":"10.1172\/JCI166847"},{"key":"26828_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41389-019-0185-4","volume":"9","author":"K Lee","year":"2020","unstructured":"Lee, K., Kitagawa, M., Liao, P. J., Virshup, D. M. & Lee, S. H. A Ras-LSD1 axis activates PI3K signaling through PIK3IP1 suppression. Oncogenesis 9, 2 (2020).","journal-title":"Oncogenesis"},{"key":"26828_CR22","doi-asserted-by":"publisher","first-page":"e2207257","DOI":"10.1002\/advs.202207257","volume":"10","author":"T Jiang","year":"2023","unstructured":"Jiang, T. et al. Targeting LncRNA DDIT4-AS1 sensitizes triple negative breast cancer to chemotherapy via suppressing of autophagy. Adv. Sci. (Weinh). 10, e2207257 (2023).","journal-title":"Adv. Sci. (Weinh)"},{"key":"26828_CR23","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.ymthe.2024.04.025","volume":"32","author":"J Lin","year":"2024","unstructured":"Lin, J. et al. Switch of ELF3 and ATF4 transcriptional axis programs the amino acid insufficiency-linked epithelial-to-mesenchymal transition. Mol. Ther. 32, 1956\u20131969 (2024).","journal-title":"Mol. Ther."},{"key":"26828_CR24","unstructured":"NCCN Clinical Practice. Guidelines in Oncology (NCCN Guidelines\u00ae), Breast Cancer, Version 2.2024, March 11, (2024)."},{"key":"26828_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12964-019-0450-3","volume":"17","author":"N Hinz","year":"2019","unstructured":"Hinz, N. & Jucker, M. Distinct functions of AKT isoforms in breast cancer: a comprehensive review. Cell. Commun. Signal. 17, 154 (2019).","journal-title":"Cell. Commun. Signal."},{"key":"26828_CR26","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/ijc.24831","volume":"126","author":"E Lopez-Knowles","year":"2010","unstructured":"Lopez-Knowles, E. et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int. J. Cancer. 126, 1121\u20131131 (2010).","journal-title":"Int. J. Cancer"},{"key":"26828_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47\u201354 (2016).","journal-title":"Nature"},{"key":"26828_CR28","doi-asserted-by":"publisher","first-page":"eabf3066","DOI":"10.1126\/science.abf3066","volume":"374","author":"M Kim","year":"2021","unstructured":"Kim, M. et al. A protein interaction landscape of breast cancer. Science 374, eabf3066 (2021).","journal-title":"Science"},{"key":"26828_CR29","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature11017","volume":"486","author":"PJ Stephens","year":"2012","unstructured":"Stephens, P. J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400\u2013404 (2012).","journal-title":"Nature"},{"key":"26828_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13058-020-01354-y","volume":"22","author":"AC Garrido-Castro","year":"2020","unstructured":"Garrido-Castro, A. C. et al. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Res. 22, 120 (2020).","journal-title":"Breast Cancer Res."},{"key":"26828_CR31","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41586-024-08031-6","volume":"635","author":"AE Schade","year":"2024","unstructured":"Schade, A. E. et al. AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of Involution. Nature 635, 755\u2013763 (2024).","journal-title":"Nature"},{"key":"26828_CR32","doi-asserted-by":"publisher","first-page":"e2407493","DOI":"10.1002\/advs.202407493","volume":"11","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. LncRNA FAISL inhibits Calpain 2-Mediated proteolysis of FAK to promote progression and metastasis of triple negative breast cancer. Adv. Sci. (Weinh). 11, e2407493 (2024).","journal-title":"Adv. Sci. (Weinh)"},{"key":"26828_CR33","doi-asserted-by":"publisher","first-page":"72990","DOI":"10.18632\/oncotarget.12166","volume":"7","author":"SQ Wang","year":"2016","unstructured":"Wang, S. Q. et al. Geridonin and Paclitaxel act synergistically to inhibit the proliferation of gastric cancer cells through ROS-mediated regulation of the PTEN\/PI3K\/Akt pathway. Oncotarget 7, 72990\u201373002 (2016).","journal-title":"Oncotarget"},{"key":"26828_CR34","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1016\/j.apsb.2022.03.023","volume":"12","author":"SQ Wang","year":"2022","unstructured":"Wang, S. Q. et al. Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor. Acta Pharm. Sin B. 12, 3263\u20133280 (2022).","journal-title":"Acta Pharm. Sin B"},{"key":"26828_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00280-018-3715-4","volume":"83","author":"SQ Wang","year":"2019","unstructured":"Wang, S. Q. et al. Steroidal dimer by001 inhibits proliferation and migration of esophageal cancer cells via multiple mechanisms. Cancer Chemother. Pharmacol. 83, 179\u2013189 (2019).","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26828-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26828-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26828-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:23:50Z","timestamp":1764325430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26828-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26828"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-26828-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal experiment was performed in accordance with guidelines of the Committee of Laboratory Animal Center of Zhengzhou University (Ethics approval license: ZZULAC2023072502). The results of animal experiments were reported according to the ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Approval of animal experiments"}},{"value":"A total of 72 cases of cancer tissue specimens and their paired adjacent normal breast tissue specimens from BC patients were obtained from the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital. This study was conducted in accordance with the criteria of the 2013 Declaration of Helsinki. This study was approved by the Medical Ethics Committee of Henan Cancer Hospital (Approval No. 2022-KY-0001-002) and informed consent was obtained from all subjects or their legal guardians.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Approval for human experiments"}}],"article-number":"42672"}}